Oral Presentation The 6th Prato Conference on Pore Forming Proteins 2025

Acidic pH can attenuate immune killing through inactivation of perforin (125619)

Adrian Hodel 1 , Jesse Rudd-Schmidt 1 , Tahereh Noori 1 , Chris Lupton 2 , Veronica CT Cheuk 1 , Joseph Trapani 3 4 , Bart Hoogenboom 5 6 , Ilia Voskoboinik 1 4
  1. Killer Cell Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
  2. Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia
  3. Cancer Cell Death Laboratory, Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia
  4. Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
  5. London Centre for Nanotechnology, University College London, London, UK
  6. Department of Physics and Astronomy, University College London, London, UK

Cytotoxic lymphocytes are crucial to our immune system, primarily eliminating virus-infected or cancerous cells via perforin/granzyme killing. Perforin forms transmembrane pores in the target cell plasma membrane, allowing granzymes to enter the target cell cytosol and trigger apoptosis. The prowess of cytotoxic lymphocytes to efficiently eradicate target cells has been widely harnessed in immunotherapies against haematological cancers. Despite efforts to achieve a similar outcome against solid tumours, the immunosuppressive and acidic tumour microenvironment poses a persistent obstacle. Using different types of effector cells, including therapeutically relevant anti-CD19 CAR T cells, we demonstrate that the acidic pH typically found in solid tumours hinders the efficacy of immune therapies by impeding perforin pore formation within the immunological synapse. Nanometre-scale study of purified recombinant perforin undergoing oligomerization reveals that pore formation is inhibited specifically by preventing the formation of a transmembrane β-barrel. The absence of perforin pore formation directly prevents target cell death. This finding uncovers a novel layer of immune effector inhibition that must be considered in the development of effective immunotherapies for solid tumours